Am J Perinatol 2015; 32(08): 803-808
DOI: 10.1055/s-0034-1396694
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Differing Effects of Resibufagenin on Cinobufatalin- versus Marinobufagenin-Induced Preeclampsia in a Rodent Model

Jules B. Puschett
1   Texas A&M Colleges of Medicine and of Veterinary Medicine and Biomedical Sciences, Texas Veterinary Medical Center, College Station, Texas
2   Scott and White Healthcare, Temple, Texas
,
Biresh Kumar
2   Scott and White Healthcare, Temple, Texas
,
M.M. Kamran Abbas
1   Texas A&M Colleges of Medicine and of Veterinary Medicine and Biomedical Sciences, Texas Veterinary Medical Center, College Station, Texas
› Author Affiliations
Further Information

Publication History

18 June 2014

29 October 2014

Publication Date:
29 December 2014 (online)

Abstract

Objective Previous studies from this laboratory have demonstrated that the bufodienolide, marinobufagenin, causes a syndrome in the pregnant rat that resembles human preeclampsia. Furthermore, marinobufagenin urinary excretion is elevated in approximately 85% of preeclamptic patients. Resibufagenin, an antagonist to marinobufagenin, completely prevents the syndrome (hypertension, proteinuria, and intrauterine growth restriction) if given from early pregnancy.

Study Design We investigated the effects of another bufodienolide, cinobufatalin, to determine if it, likewise, could induce the rat “preeclamptic” syndrome, which it did. We then examined whether resibufagenin could prevent the syndrome due to cinobufatalin.

Results Resibufagenin improved hypertension but not proteinuria, and did not prevent uterine growth restriction.

Conclusion We conclude that more than one bufodienolide may induce the preeclamptic syndrome and that each may require a specific antagonist to prevent (or treat) the syndrome.